The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.
 
Jian Zhou
No Relationships to Disclose
 
Jia Fan
No Relationships to Disclose
 
Fang-Ming Gu
No Relationships to Disclose
 
Tao Li
No Relationships to Disclose
 
Dou-Sheng Bai
No Relationships to Disclose
 
Hui-Chuan Sun
Employment - Zhongshan Hospital, Fudan University
Honoraria - AstraZeneca; Bayer; BeiGene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche; TopAlliance BioSciences Inc; Zelgen
Research Funding - Innovent Biologics (Inst); MSD (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Radiomic features to predict tumor response to systemic therapy in liver cancer patients (Inst)
 
Zheng Wang
No Relationships to Disclose
 
Shuang-Jian Qiu
No Relationships to Disclose
 
Qing-Hai Ye
No Relationships to Disclose
 
Ying-Hong Shi
No Relationships to Disclose
 
Qiang Gao
No Relationships to Disclose
 
Xiao-Ying Wang
No Relationships to Disclose
 
Xin-Rong Yang
No Relationships to Disclose
 
Guo-Ming Shi
No Relationships to Disclose
 
Yuan-Fei Peng
No Relationships to Disclose